Adverse Events Occurred within 30 Minutes Following COVID-19 Vaccination at Bang Sue Central Vaccination Center, Bangkok, Thailand, July to December 2021
DOI:
https://doi.org/10.59096/osir.v17i4.268653Keywords:
Adverse events following immunization, COVID-19, COVID-19 vaccine, Immunization, ThailandAbstract
COVID-19, with a case fatality rate of 0.98%, requires treatment based on severity of illness. Vaccination is crucial for preventing virus spread and decreasing severity of illness, yet it may lead to side effects. This study explored the 30-minute adverse events following immunization (AEFI) after receiving COVID-19 vaccination at Bang Sue Central Vaccination Center (BSCVC). Data (demographic profile of vaccines, type of vaccines administered for the first and second doses and occurrence of AEFI within 30 minutes) from 871,446 vaccine administrations from July to December 2021 at BSCVC were analyzed. There were 386 occurrences (44.29 per 100,000 doses of vaccine administered) of 30-minute AEFI, with females experiencing AEFI twice as often as males. The highest AEFI rate was with the ChAdOx1 nCoV-19 vaccine (62.68 cases per 100,000 vaccinations). First doses resulted in nearly four times more AEFI than second doses. When considering the second dose, the heterologous regimens had more AEFI than the homologous regimens. Common AEFI symptoms included dizziness/lightheadedness (34%), palpitations/chest tightness (16%), and numbness (11%). No serious AEFI was observed. Further monitoring of AEFI across all vaccination centers in the country should be done including causality assessments for any serious AEFI reported.
References
Leelarasamee A. Interesting facts about COVID-19 infection from the virus [Internet]. Nonthaburi: Medical Council of Thailand; 2022 [cited 2022 Jan 1]. 10 p. <https://tmc.or.th/covid19/download/pdf/tmc-covid19-19.pdf>. Thai.
Department of Disease Control, Ministry of Public Health (TH). Summary of the COVID-19 situation in Thailand [Internet]. Bangkok: COVID-19 Information, The Government Public Relations Department; 2021 [cited 2022 Jan 1]. <https://www.facebook.com/informationcovid19>
Department of Disease Control, Ministry of Public Health (TH). Guidelines for the prevention of coronavirus disease 2019 (COVID-19) or COVID 19 for the general public and at-risk groups [Internet]. Nonthaburi: Department of Disease Control; 2021 [cited 2022 Jan 1]. <https://ddc.moph.go.th/viralpneumonia/int_protection.php>. Thai.
Department of Disease Control, Ministry of Public Health (TH). Guidelines for COVID-19 vaccination in the 2021 Thai epidemic situation (2nd revision). Nonthaburi: Division of Communicable Disease, Department of Disease Control, Ministry of Public Health; 2021 Aug. 98 p. Thai.
Thailand Working Group on the Treatment and Prevention of Severe Allergy. Clinical practice guidelines for anaphylaxis 2017 [Internet]. Bangkok: The Allergy, Asthma, and Immunology Association of Thailand; 2017 [cited 2022 Jan 1]. 34 p. <https://www.allergy.or.th/2016/pdf/Thai_CPG_Anaphylaxis_2017_Full_version.pdf>. Thai.
Zahid MN. Unfolding the mild to moderate short-term side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study. Vaccines (Basel). 2021;9(11):1369. doi:10.3390/vaccines9111369.
Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physiol. 2018 Dec:6:16–20. doi:10.1016/j.cophys.2018.03.010.
Fish EN. The X-files in immunity: Sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8(9):737–44. doi:10.1038/nri2394.
Yin A, Wang N, Shea PJ, Rosser EN, Kuo H, Shapiro JR, et al. Sex and gender differences in adverse events following influenza and COVID-19 vaccination. Biol Sex Differ. 2024 Jun 18;15(1):50. doi:10.1186/s13293-024-00625-z.
Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019 Mar;41(2):239–49. doi:10.1007/s00281-018-0726-5.
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016 Oct;16(10):626–38. doi:10.1038/nri.2016.90.
Joshi RK, Muralidharan CG, Gulati DS, Mopagar V, Dev JK, Kuthe S, et al. Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Med J Armed Forces India. 2021 Jul;77(Suppl 2):S505–7. doi:10.1016/j.mjafi.2021.05.011.
Jeon M, Kim J, Oh CE, Lee JY. Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea. Vaccines (Basel). 2021 Sep 28;9(10):1096. doi:10.3390/vaccines9101096.
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939–49. doi:10.1016/S1473-3099(21)00224-3.
Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283–8. doi:10.15585/mmwr.mm7008e3.
Nettelfield S, Yu D, Canete PF. Systemic immunometabolism and responses to vaccines: insights from T and B cell perspectives. Int Immunol. 2023 Dec 23;35(12):571–82. doi:10.1093/intimm/dxad021.
Wong LP, Lai LL, See MH, Alias H, Syed Omar SF, Ng CG, et al. Adverse events following immunization and psychological distress among cancer patients/survivors following vaccination against SARS-CoV-2 infection. Front Psychol. 2022 Jul 26;13:906067. doi:10.3389/fpsyg.2022.906067.
Eterafi M, Fouladi N, Golizadeh M, Shaker H, Matin S, Safarzadeh E. Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. PLoS One. 2024 Jan 5;19(1):e0296669. doi:10.1371/journal.pone.0296669.
Haider T, Ali J, Ali SM, Iftikhar AS, Siddiqui AA, Khan AS, et al. Prevalence of side effects of the AstraZeneca COVID-19 vaccine: a multicenter experience from Pakistan. Cureus. 2023 Oct 5;15(10):e46543. doi:10.7759/cureus.46543.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines (Basel). 2021;9(6):674. doi:10.3390/vaccines9060674.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Outbreak, Surveillance, Investigation & Response (OSIR) Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
